CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Ginkgo Enters Into A Definitive Agreement To Acquire Zymergen

Ginkgo Enters Into A Definitive...

Exocel Bio Ushers In The Next Generation Of Regenerative Aesthetics With All-Natural Exosomes Serum, Exovextm

Exocel Bio Ushers In The Next...

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Antibodies: The Building Blocks of Cures

Antibodies: The Building Blocks of Cures

The Dynamic Commercial Aspects of Life Sciences

The Dynamic Commercial Aspects of...

The Future of Life Sciences Industry

The Future of Life Sciences Industry

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Accelerating Digital Transformation...

Re-imagining Learning in a Post-Pandemic World

Re-imagining Learning in a...

Ginkgo Enters Into A Definitive Agreement To Acquire Zymergen

Ginkgo Enters Into A Definitive...

Exocel Bio Ushers In The Next Generation Of Regenerative Aesthetics With All-Natural Exosomes Serum, Exovextm

Exocel Bio Ushers In The Next...

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Antibodies: The Building Blocks of Cures

Antibodies: The Building Blocks of Cures

The Dynamic Commercial Aspects of Life Sciences

The Dynamic Commercial Aspects of...

The Future of Life Sciences Industry

The Future of Life Sciences Industry

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Accelerating Digital Transformation...

Re-imagining Learning in a Post-Pandemic World

Re-imagining Learning in a...

Three Problems Faced By Biotech Companies

Life Sciences Review | Thursday, July 14, 2022
Tweet

The average time it seizes to develop a treatment, gain regulatory approval, and bring a product to market is 15 years; companies often invest more than a decade in a product before seeing a return.


FREMONT, CA: The COVID-19 pandemic emphasized the importance of innovative medical treatments, resulting in new research, product approval, and financing opportunities. Nevertheless, keeping expenditures under control and increasing budget efficiency is a never-ending problem. As more rivals enter the industry, the requirement of hiring and maintaining top staff grows, and companies must stay on top of inconstant drug compliance rules.


Here are three problems facing biotech companies:


Regulatory Standards


Regulatory agencies amended guidelines in 2020 to help biotech businesses perform COVID-19 vaccine research. The revised guidelines lowered the huge compliance burden faced by biotech companies, but companies are skeptical that the user-friendly modifications will stick.


Biotech and life sciences companies in Europe have compliance issues. While the European Union started the General Data Protection Regulation (GDPR) to clarify compliance rules, businesses must still juggle competing obligations from several organizations and governments.


Maximizing Cost-Effectiveness


Funding research to combat health risks such as COVID-19, cancer, and Alzheimer's is costly. For medicine, companies can spend up to one billion dollars on research and development.


The average time it seizes to develop a treatment, gain regulatory approval, and bring a product to market is 15 years; companies often invest more than a decade in a product before seeing a return.


Procurement of critical medicine components is delayed as global supply chains remain hindered by the pandemic, lengthening the entire process.


It is no surprise that many biotech and life science companies consider cost containment a major hurdle because of high internal costs and a lengthy process before making income.


Skill Shortage


While the epidemic expanded demand for biotech's cutting-edge medical solutions, it also worsened a long-standing problem for companies: attracting and retaining top people. Due to the skills scarcity, biotech HR departments must devote a significant amount of time and resources to hiring new employees. HR teams are under enormous pressure to keep every workforce member due to the lengthy and resource-intensive recruitment process.


Companies lose efficiency when employees leave, and HR departments must repeat the recruitment and onboarding process. Turnover costs are well-documented, ranging from 33% of an employee's compensation to a whopping 213% for highly educated executive jobs. While the actual cost of losing and substituting significant individuals varies, one thing is certain: biotech businesses already functioning on tight budgets cannot afford to lose more employees.


Weekly Brief

loading
Top 10 Biotech Companies in Latin America - 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/three-problems-faced-by-biotech-companies-nwid-895.html